GlassScriptPhysician profile
Zahida S Tayyib
NPI 1144251315
$6,505.09
in general payments reported to CMS, 2019-2025
22 companies · $398 in 2025
The $398 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,515 · 2020: $377 · 2021: $275 · 2022: $1,019 · 2023: $1,724 · 2024: $1,197 · 2025: $398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,318.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,181.32 | 2021-2025 | Vraylar |
| Lundbeck LLC | $809.50 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Teva Pharmaceuticals USA, INC. | $728.24 | 2022-2025 | Austedo Xr, Uzedy, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $508.35 | 2021-2025 | Caplyta |
| Alkermes, INC. | $455.77 | 2020-2024 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $414.70 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $375.41 | 2019-2024 | Trintellix |
| Neurocrine Biosciences, INC. | $354.72 | 2019-2024 | Ingrezza |
| Allergan, INC. | $338.77 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $292.81 | 2019-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $223.97 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $210.58 | 2019-2025 | Spravato |
| Bausch Health US, LLC | $193.93 | 2022-2025 | Aplenzin |
| Supernus Pharmaceuticals, INC. | $97.13 | 2023-2024 | Qelbree, Qelbree |
| Adlon Therapeutics L.P. | $70.50 | 2019-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $56.71 | 2022 | |
| Almatica Pharma LLC | $56.11 | 2024 | Loreev Xr |
| Noven Therapeutics, LLC | $48.76 | 2024 | Xelstrym |
| Corium, LLC | $24.97 | 2022 | |
| Idorsia Pharmaceuticals US INC | $21.90 | 2023 | Quviviq |
| Shire North American Group INC | $20.53 | 2019 | |
| Indivior INC. | $20.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zahida Tayyib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.